Barter David sold $136K of CLBT

Barter David (Chief Financial Officer) sold 12,134 shares of Cellebrite DI Ltd. (CLBT) at $11.21 ($0.14M total) on 2026-10-16.

Original reporting
SEC EDGAR · Barter David
Published Oct 19, 2026, 10:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

A modest insider sell typically has limited price impact unless part of a larger trend.

02

Market read

Small insider sale; unlikely to move the stock significantly.

03

What to watch

Potential tax planning or portfolio rebalancing by the CFO.

Relevance 4/10Novelty 4/10Timing: today

Background

Form 4 filings provide the first public disclosure of insider trades.

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

CFO Barter David sold 12,134 shares for $136K in an open‑market transaction disclosed on Form 4.

Expected impact

likely modest pressure as the market prices in the insider sell

Evidence & confidence

Sale size is small relative to holdings; no 10b5‑1 plan; typical insider sell impact is limited.

Market effects

Minimal impact on the digital forensics sector; no broader industry signal.

US market only; no regional effect.

Low; isolated insider transaction.

Counterpoint

The sale could be unrelated to fundamentals and may not affect price.

Key entities

  • Cellebrite DI Ltd.

    Provider of digital intelligence solutions, listed on NASDAQ.

  • Barter David

    Chief Financial Officer of Cellebrite.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTHighAI 8/10

Cellebrite DI Ltd. (CLBT): Financial results for Q3 2026

Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and

$CLBTHigh

Cellebrite Reports Third-Quarter 2026 Results

Cellebrite reported Q3 2026 results with ARR up 20% to $528.5M, revenue up 18% to $149M, and adjusted EBITDA of $53.6M. CEO Shiv Ramji highlighted strong international and U.S. Federal performance, and raised 2026 adjusted EBITDA outlook to $163M-$166M. The company also announced plans to redomicile in the U.S. and progress with its Genesis AI solution.

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.